Table 2.
Adverse events, according to dose level, associated with treatment with vemurafenib in combination with irinotecan and cetuximab.
| Total | Grade 1 | Grade 2 | Grade 3 | Grade 4 | Grade 1–2 | Grade 3–4 | Total | % |
|---|---|---|---|---|---|---|---|---|
| Alopecia | 3 | 1 | 1 | 4 | 1 | 5 | 26 | |
| Anemia | 7 | 6 | 2 | 13 | 2 | 15 | 79 | |
| Anorexia | 7 | 3 | 10 | 0 | 10 | 53 | ||
| Arthralgia | 5 | 1 | 2 | 6 | 2 | 8 | 42 | |
| Blurry vision | 1 | 1 | 0 | 1 | 5 | |||
| Constipation | 4 | 4 | 0 | 4 | 21 | |||
| Cramping | 1 | 1 | 0 | 1 | 5 | |||
| Diarrhea | 6 | 5 | 5 | 11 | 5 | 16 | 84 | |
| Dry heaves | 1 | 1 | 0 | 1 | 5 | |||
| Dry mouth | 1 | 1 | 0 | 1 | 5 | |||
| Dyspnea | 4 | 1 | 5 | 0 | 5 | 26 | ||
| Epistaxis | 1 | 1 | 0 | 1 | 5 | |||
| Fatigue | 9 | 6 | 2 | 15 | 2 | 17 | 89 | |
| Fever | 1 | 1 | 0 | 1 | 5 | |||
| Flushing | 1 | 1 | 0 | 1 | 5 | |||
| GERD | 1 | 1 0 | 1 5 | |||||
| HFS | 2 | 2 | 0 | 2 | 11 | |||
| HTN | 1 | 1 | 0 | 1 | 5 | |||
| Inc bilirubin | 1 | 1 | 0 | 1 | 5 | |||
| Inc LFT | 1 | 1 | 0 | 1 | 5 | |||
| Infection | 1 | 1 | 0 | 1 | 5 | |||
| Leukopenia | 2 | 3 | 3 | 1 | 5 | 4 | 9 | 47 |
| Low albumin | 1 | 1 | 0 | 1 | 5 | |||
| Low K | 1 | 1 | 0 | 1 | 5 | |||
| Low Mg | 2 | 2 | 0 | 2 | 11 | |||
| Mucositis | 4 | 1 | 5 | 0 | 5 | 26 | ||
| Myalgia | 9 | 2 | 11 | 0 | 11 | 58 | ||
| Nausea | 11 | 3 | 1 | 14 | 1 | 15 | 79 | |
| Neuropathy | 4 | 2 | 6 | 0 | 6 | 32 | ||
| Proteinuria | 1 | 1 | 0 | 1 | 5 | |||
| Pruritis | 1 | 1 | 0 | 1 | 5 | |||
| Rash | 12 | 1 | 1 | 13 | 1 | 14 | 74 | |
| Taste change | 1 | 1 | 0 | 1 | 5 | |||
| Taste change | 1 | 1 | 0 | 1 | 5 | |||
| Vomiting | 5 | 1 | 6 | 0 | 6 | 32 | ||
| Weight loss | 1 | 1 | 2 | 0 | 2 | 11 |